louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT01610778: Effects of 5-Aminolevulinic Acid on Glucose Metabolism
Official title: A Randomized, Double-blind, Cross-over Study to Assess Efficacy of 5-Aminolevulinic Acid in Type 2 Diabetic Patients on Medication.
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Type 2 Diabetes on Medication
Lead sponsor: Hiroshima University
Sponsor class: OTHER
Collaborators: name: SBI Pharmaceuticals Co, Ltd.
First posted: 2012-06-04
Enrollment: 35
Sex: ALL
Minimum age (years): 35
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: PREVENTION

Brief summary: This study is designed to evaluate efficacy of 5-aminolevulinic acid in subjects with type 2 diabetes on medication.


Eligibility criteria: Inclusion Criteria:

* Type 2 diabetic patients on medication
* HbA1c ≤ 9.0% (as JDS values, which is equivalent to HbA1c ≤ 9.4% as NGSP values)
* On stable treatment of diabetes for at least the last 3 months
* With permission to attend the clinical trial from the primary doctor

Exclusion Criteria:

* On insulin therapy
* BMI ≤ 18 kg/m2 or ≥ 30 kg/m2
* History of porphyria, hemochromatosis, or viral hepatitis
* Pregnant or nursing a child
* Heart disease
* Renal or hepatic dysfunction
* Participation in any clinical trial within 90 days of the commencement of the trial

Primary outcomes:
measure: Fasting glucose level
timeFrame: Every 4 weeks (Overall 36 weeks)
measure: HbA1c level
timeFrame: Every 4 weeks (Overall 36 weeks)
measure: Glycoalbumin level
timeFrame: Every 4 weeks (Overall 36 weeks)
Secondary outcomes:
measure: Fasting insulin level
timeFrame: Every 4 weeks (Overall 36 weeks)
measure: 1,5-AG level
timeFrame: Every 4 weeks (Overall 36 weeks)
measure: Serum C-peptide level
timeFrame: Every 4 weeks (Overall 36 weeks)
measure: HOMA-R
timeFrame: Every 4 weeks (Overall 36 weeks)
Other outcomes:
Locations:
city: Hiroshima
country: Japan
facility: Hiroshima University
Study officials:
References:
Clinical trial NCT03307278: House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance
Official title: Effects and Mechanism of House Dust Mite Induced Inflammasome Activation on Corticosteroid Resistance
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Allergic Asthma
Lead sponsor: China Medical University Hospital
Sponsor class: OTHER
First posted: 2017-10-11
Enrollment: 0
Sex: ALL
Minimum age (years): 20
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: In this project, PBMCs will be isolated from HDM allergic and non allergic patient and then stimulated with HDM crude extract. The expression of inflammasome and the correlation of inflammasome activation and steroid resistance will be investigated.


Eligibility criteria: Inclusion Criteria:

* HDM allergic and non allergic subjects

Exclusion Criteria:

* Pregnant subject, cancer

Primary outcomes:
measure: inflammasome activation by HDM
timeFrame: 6 hours
measure: Steroid receptor phosphorylation by HDM
timeFrame: 6 hours
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT05150678: Removal Versus Non Removal of Ceserean Section Scar .
Official title: EXCISION of CAESAREAN SECTION SKIN SCAR AND SUBCUTANEOUS RELEASE VERSUS NON REMOVAL IN REPEATED CAESAREAN SECTION.
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Cesarean Wound; Dehiscence
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2021-12-09
Enrollment: 600
Sex: FEMALE
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: there are two gruops in the study ;one with removal of the scar 2nd with non removal in repeated cs
Primary purpose: OTHER

Brief summary: EXCISION of cs section skin scar and subcutaneous release versus non removal in repeated cs .aRandomized controlled trial .

Detailed description: All eligible participants will randimized into two groups ; gruop 1 skin removal in which we will going to remove skin scar gruop 2 skin non removal ;direct open in the middle of the previous scar Follow up will be recorded for each participant aphoto will be taken postoperative to score the healing of the wound the follow up will be at one week ,then one month ,then three month acomparison between the two groups will be done .

Eligibility criteria: Inclusion Criteria:

1. women with repeated ceserean section
2. pregnant women \>32 wk

Exclusion Criteria:

* DM bleeding tendency preeclampsia previous history of wound infection chronic steroid use women refused to participate in Randomized clinical trial

Primary outcomes:
measure: the healing score
timeFrame: through the study duration AVERAGE ONE YEAR.
Secondary outcomes:
measure: the cosmotic appereance of the scar
timeFrame: through the study duration an average one year
Other outcomes:
Locations:
Study officials:
References:
citation: Altman AD, Allen VM, McNeil SA, Dempster J. Pfannenstiel incision closure: a review of current skin closure techniques. J Obstet Gynaecol Can. 2009 Jun;31(6):514-520. doi: 10.1016/S1701-2163(16)34213-X.
citation: Kawakita T, Landy HJ. Surgical site infections after cesarean delivery: epidemiology, prevention and treatment. Matern Health Neonatol Perinatol. 2017 Jul 5;3:12. doi: 10.1186/s40748-017-0051-3. eCollection 2017.
Clinical trial NCT04598178: Normative Data for the Qmci-TW in a Taiwanese Sample
Official title: Normative Data for the Quick Mild Cognitive Impairment-Taiwan Version (Qmci- TQ) in a Taiwanese Sample
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Postoperative Cognitive Dysfunction
Lead sponsor: National Taiwan University Hospital
Sponsor class: OTHER
First posted: 2020-10-22
Enrollment: 30
Sex: ALL
Minimum age (years): 20
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Normative taiwan people

Brief summary: Many perioperative factors have been pointed out as the risk factors for postoperative cognitive dysfunction, which may occur immediately after the surgery, days after the surgery, or months after the surgery. Quick mild cognitive impairment screen (Qmci) is a sensitive and specific test to differentiate mild postoperative cognitive dysfunction. However, the learning effect have been raised as a bias when we repeated the same test for one person at different timing. Thus the study is designed to collected the Normative Data in series for the Qmci-TW in a Taiwanese Sample.


Eligibility criteria: Inclusion Criteria:

* adults no less than 20years old

Exclusion Criteria:

* pregnant women
* patients with respiratory failure \[forced expiratory volume at one second (FEV1)/ forced vital capacity (FVC) \< 70 % and FEV1 \< 50%\]
* patients with heart failure(NYHA score =III、IV)
* patients with chronic kidney disease (eGFR\< 60 ml.min-1.1.73m-2)
* patients with liver failure
* patients with ongoing infection
* patients have surgery or hospital admission in the past half year

Primary outcomes:
measure: cognitive function by the Taiwan version of questionnaire Qmci (Qmci-TW)
timeFrame: 180 days
Secondary outcomes:
Other outcomes:
Locations:
city: Taipei
country: Taiwan
facility: NTUH, Taipei, Taiwan
Study officials:
affiliation: National Taiwan University Hospital
name: Fon-Yih Tsuang, Ph.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Steinmetz J, Christensen KB, Lund T, Lohse N, Rasmussen LS; ISPOCD Group. Long-term consequences of postoperative cognitive dysfunction. Anesthesiology. 2009 Mar;110(3):548-55. doi: 10.1097/ALN.0b013e318195b569.
citation: Alam A, Hana Z, Jin Z, Suen KC, Ma D. Surgery, neuroinflammation and cognitive impairment. EBioMedicine. 2018 Nov;37:547-556. doi: 10.1016/j.ebiom.2018.10.021. Epub 2018 Oct 19.
citation: Monk TG, Weldon BC, Garvan CW, Dede DE, van der Aa MT, Heilman KM, Gravenstein JS. Predictors of cognitive dysfunction after major noncardiac surgery. Anesthesiology. 2008 Jan;108(1):18-30. doi: 10.1097/01.anes.0000296071.19434.1e.
citation: Lee MT, Chang WY, Jang Y. Psychometric and diagnostic properties of the Taiwan version of the Quick Mild Cognitive Impairment screen. PLoS One. 2018 Dec 3;13(12):e0207851. doi: 10.1371/journal.pone.0207851. eCollection 2018.
Clinical trial NCT06949878: 21% Hydrochloric Acid Based Versus 6.6 % Hydrochloric Based Micro Abrasive Kit in Management of Patients With Mild to Moderate Fluorosis
Official title: Clinical Evaluation of Different Concentrations of Hydrochloric Acid Based as Micro Abrasive Kits in Management of Patients With Mild to Moderate Fluorosis (A 6month Randomized Clinical Trial)
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: PHASE4
Conditions: Enamel Discoloration
Fluorosis, Dental
Keywords: Dental fluorosis
Microabrasion
Enamel Discoloration
Patient Reported Outcome Measures
Randomized clinical trial
High consentration hydrochloric acid based microabrasive kit(Antivet)
Low consentration hydrochloric acid based microabrasive kit ( opalustre)
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2025-04-29
Enrollment: 35
Sex: ALL
Minimum age (years): 15
Maximum age (years): 45
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: compare the clinical performance of different concentrations of hydrochloric acid based as micro abrasive kits in management of patients with mild to moderate fluorosis over 6month follow up .

Detailed description: microabrasion is a permanent cosmetic dentistry treatment indeed to preserve the health of all part of any defect in enamel.

Eligibility criteria: Inclusion Criteria:

Patients who wanted to change the appearance of their stained teeth Males or females. Patients with three or more stained incisors and canines Patients willing and able to attend periodic follow-up visits Patient concerning with oral health. Co-operative patients who show interest to participate in the study.

Exclusion Criteria:

Patients with known allergic or adverse reaction to the tested materials. Smoking habit Patients having Poor oral hygiene Patients with special health care needs or any systemic disease that may affect treatment Patients participating in other dental studies. Patients suffering from white spot lesion, hypoplasia, amelogenesis imperfecta, dentinogenesis imperfecta, or badly broken and missing teeth due to MIH.

Participants who had a history of dental bleaching.

Primary outcomes:
measure: Clinical assessment of treatment success
timeFrame: T( Time ) T0(base line )=Immediately , T1 = 3 Months , T2 = 6 Month
Secondary outcomes:
measure: Clinical evaluation of Sensitivity
timeFrame: Time frame : T( Time ) T0(base line )=Immediately , T1 = 3 Months , T2 = 6 Month
measure: Patient satisfaction with the Treatment.
timeFrame: Time frame : T( Time ) T0(base line )=Immediately , T1 = 3 Months , T2 = 6 Month
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03530878: Mild Hip Dysplasia
Official title: Periacetabular Osteotomy Versus Arthroscopic Management of Mild Hip Dysplasia: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Hip Dysplasia
Lead sponsor: Mayo Clinic
Sponsor class: OTHER
First posted: 2018-05-21
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 45
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Hip dysplasia is a complex problem that exists on a spectrum from mild to severe disease. Periacetabular osteotomy (PAO) remains the gold standard for most patients with dysplasia; however, the procedure is quite invasive making the decision to proceed in cases of mild disease difficult. Hip arthroscopy (HA) is an alternative minimally invasive technique that can be used to address mild dysplasia. Nevertheless, HA has less capability for correction and in rare instances can exacerbate instability in the dysplastic hip. There is a paucity of data examining outcomes between these two treatment strategies for this challenging problem.

Detailed description: The Bernese periacetabular osteotomy (PAO) remains the gold standard for treatment of symptomatic developmental dysplasia of the hip (DDH) in most patients with closed triradiate cartilage. First developed by Ganz in 1984, this technique utilizes 4 osteotomies to completely mobilize the acetabular fragment 1. Although a technically demanding procedure, it allows optimal correction in all planes and maintains integrity of the posterior column, enabling early weight bearing and mobilization. Several groups have confirmed the long-term efficacy of this joint preservation procedure with a recent report from the inventing institution documented impressive survivorship up to 30 years after surgery 2. Treatment with PAO is more controversial for mild forms of dysplasia where the lateral center-edge angle (LCEA) is 18° - 25° and/or the Tӧnnis angle is 8° - 15°. In these patients the delta correction is more limited, thus creating a more unpredictable result with equally invasive surgery.

Eligibility criteria: Inclusion Criteria:

* Diagnosis of symptomatic mild DDH
* Lateral center-edge angle 18° - 25° and/or Tӧnnis angle 8° - 15°
* Skeletally mature
* Age 18 - 45
* Tonnis Grade 0 or 1 osteoarthritis (minimal or no arthritis)
* Ability to receive a standard of care preoperative MRI arthrogram of the hip

Exclusion Criteria:

* Pregnant women
* Neurogenic dysplasia
* Legg-Calvé-Perthes disease
* Previous surgery about the hip including previous hip arthroscopy to address intra-articular pathology

Primary outcomes:
measure: The Forgotten Joint Score-12 (FJS-12)
timeFrame: 1 year
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Mayo Clinic
name: Rafael J Sierra
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00888771: Discard:Characterisation of Colonic Polyps in Vivo
Official title: Characterisation of Small Colonic Polyps in Vivo
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Colorectal Polyps
Keywords: Colorectal cancer
polyps
colonoscopy
advanced imaging
Lead sponsor: Imperial College London
Sponsor class: OTHER
First posted: 2009-04-28
Enrollment: 130
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study group therefore would comprise those presenting for 3 yearly follow up or sooner i.e. those with a resected colorectal cancer or those with ≥ three adenomas or one advanced ≥10mm adenoma or those with a positive faecal occult blood test

Brief summary: Prospective study of accuracy of colonic polyp characterisation in vivo using high resolution white light endoscopy, narrow band imaging and chromoendoscopy.


Eligibility criteria: Inclusion Criteria:

1. Patients over 18 years of age, assessed as fit for routine colonoscopy
2. Patients attending for screening or surveillance colonoscopy meeting the following criteria:

   * Polyp surveillance with at least 3 adenomas or 1 adenoma\>10mm at previous colonoscopy
   * Surveillance post colorectal cancer resection
   * Screening with positive faecal occult blood test

Exclusion Criteria:

1. Patients with known colitis or polyposis syndromes
2. Unable or unwilling to give informed consent

Primary outcomes:
measure: Accuracy of polyp characterisation
timeFrame: 12 months
Secondary outcomes:
measure: Change in surveillance interval after formal histopathology
timeFrame: 12 months
Other outcomes:
Locations:
city: Harrow
country: United Kingdom
facility: Wolfson Unit for Endoscopy, St Mark's Hospital
state: Moddlesex
Study officials:
affiliation: Wolfson Unit for Endoscopy, St Mark's Hospital
name: Brian P Saunders, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Ignjatovic A, East JE, Suzuki N, Vance M, Guenther T, Saunders BP. Optical diagnosis of small colorectal polyps at routine colonoscopy (Detect InSpect ChAracterise Resect and Discard; DISCARD trial): a prospective cohort study. Lancet Oncol. 2009 Dec;10(12):1171-8. doi: 10.1016/S1470-2045(09)70329-8. Epub 2009 Nov 10.
Clinical trial NCT05548478: Corneal Endothelial Cell Injury Induced by Mitomycin-C
Official title: Corneal Endothelial Cell Injury Induced by Mitomycin-C in TransEpi Single Step and Alcohol Assisted Photorefractive Keratectomy PRK: A Comparative Study
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Myopia
Keywords: mytomycin
Lead sponsor: Al-Azhar University
Sponsor class: OTHER
First posted: 2022-09-21
Enrollment: 60
Sex: ALL
Minimum age (years): 17
Maximum age (years): 50
Standard ages: CHILD
ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: our study will investigate the effecacy of Mitomycin-C in TransEpi single step photorefractive keratectomy (PRK) and alcohol assisted PRK


Eligibility criteria: Inclusion Criteria:

* Age over 18 years.
* Primary myopia or compound myopic astigmatism.
* Preoperative manifest refraction spherical equivalent (MRSE) within the range of -1.0 to 8 D
* Stable refractive error for at least 12 months before the surgery.
* Contact lens discontinuation for at least 3 weeks.
* Estimated corneal stromal bed thickness of more than 300mm at the thinnest point

Exclusion Criteria:

* Unwilling to participate in the study.
* Previous ocular surgery
* Any diagnosed ocular disease
* History of ocular trauma

Primary outcomes:
measure: Endothelial cell Density
timeFrame: Base line
measure: Endothelial cell Density
timeFrame: at 1st month
measure: Endothelial cell Density
timeFrame: at 3rd month
Secondary outcomes:
Other outcomes:
Locations:
city: Damieta
country: Egypt
facility: Ehab tharwat
state: New Damietta
Study officials:
References:
Clinical trial NCT06986278: tdCS Combined With Treadmill Training in Patients With Multiple Sclerosis
Official title: Transcranial Direct Current Stimulation Combined With Treadmill Training With Partial Body Weight Support in Patients With Multiple Sclerosis
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: tDCS
Sham tDCS
Keywords: tdcs
gait
multiple sclerosis
gait training
Lead sponsor: University of Castilla-La Mancha
Sponsor class: OTHER
Collaborators: name: Asociación Esclerosis Múltiple de Toledo, España
First posted: 2025-05-22
Enrollment: 78
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This clinical trial aims to evaluate the therapeutic effectiveness of transcranial direct current stimulation (tDCS), a non-invasive technique that modulates cortical excitability, in combination with gait training in patients with multiple sclerosis (MS). The study focuses on improving balance and walking ability, which are commonly impaired in this population. A randomized, triple-blind, controlled design will be used, comparing an active tDCS group with a sham stimulation group, both receiving the same gait training protocol. Outcomes will include functional and clinical measures related to mobility, balance, and fatigue. The project builds on previous meta-analytical evidence suggesting positive effects of tDCS in MS and aims to confirm these findings using an optimized stimulation protocol.


Eligibility criteria: Inclusion Criteria:

* Ability to understand and follow instructions.
* Diagnosis of Multiple Sclerosis according to McDonald criteria.
* Expanded Disability Status Scale (EDSS) between 1 and 6.
* Stable condition in the last three months.

Exclusion Criteria:

* Peripheral neurological injury of lower limbs.
* Metal objects in the head.
* Uncontrolled epilepsy.
* Diagnosis of psychiatric disorder.
* Fractures or fissures in the skull.
* Presence of any implanted electronic device (pacemaker, baclofen pump).
* Presence of ulcers in the harness attachment area.
* Osteoporotic fractures in the last 2 years.
* Height \> 190 cm.
* Weight \> 120 kg.

Primary outcomes:
measure: TUG
timeFrame: Pre intervention, at the end of 10th session, and follow-up at 4 weeks
measure: Timed 25-Foot Walk
timeFrame: Pre intervention, at the end of 10th session, and follow-up at 4 weeks
Secondary outcomes:
measure: MSWS-12
timeFrame: Pre intervention, at the end of 10th session, and follow-up at 4 weeks
measure: FSS
timeFrame: Pre intervention, at the end of 10th session, and follow-up at 4 weeks
Other outcomes:
measure: Adverse events
timeFrame: 24 hours after the stimulation
measure: Borg
timeFrame: Before stimulation and just immediately after stimulation ends
Locations:
city: Toledo
country: Spain
facility: Asociación de Esclerosis Múltiple de Toledo
city: Toledo
country: Spain
facility: Universidad de Castilla La Mancha
Study officials:
References:
Clinical trial NCT06275178: Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study
Official title: Medical Thoracoscopy for Diagnosing Unexplained Pleural Effusion: a National Multicenter Retrospective Study
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Pleural Effusion
Pleural Effusion, Malignant
Fibrinous Pleuritis
Lead sponsor: China-Japan Friendship Hospital
Sponsor class: OTHER
First posted: 2024-02-23
Enrollment: 5000
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients with pleural effusion who underwent medical thoracoscopy were included in the study. Patients who could not obtain a final diagnosis were excluded from the study

Brief summary: This study is a national multicenter retrospective study. Patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy for patients in recent 10 years were retrospectively collected from multiple centers to understand the proportion and final etiological composition of pleural effusion in China.


Eligibility criteria: Inclusion Criteria:

Patients with unexplained pleural effusion who underwent thoracoscopic or video-assisted thoracoscopic biopsy

Exclusion Criteria:

Patients who cannot obtain a final diagnosis

Primary outcomes:
measure: The proportion of fibrinous pleurisy in Chinese population
timeFrame: December 31, 2024
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
References: